Combining associative classification with multifactor dimensionality reduction for predicting higher-order SNP interactions in case-control studies

2020 ◽  
Vol 2 (1) ◽  
pp. 48
Author(s):  
Suneetha Uppu ◽  
Raj P. Gopalan ◽  
Aneesh Krishna
Keyword(s):  
Dimensionality Reduction ◽  
Multifactor Dimensionality Reduction ◽  
Case Control ◽  
Higher Order ◽  
Associative Classification ◽  
Case Control Studies

scholarly journals Model-Based Multifactor Dimensionality Reduction for detecting epistasis in case-control data in the presence of noise

2010 ◽  
Vol 75 (1) ◽  
pp. 78-89 ◽  
Author(s):  
Tom Cattaert ◽  
M. Luz Calle ◽  
Scott M. Dudek ◽  
Jestinah M. Mahachie John ◽  
François Van Lishout ◽  
...  
Keyword(s):  
Dimensionality Reduction ◽  
Multifactor Dimensionality Reduction ◽  
Case Control ◽  
Control Data ◽  
Model Based

Case-Control Studies

2009 ◽  
Author(s):  
Ruth H. Keogh ◽  
D. R. Cox
Keyword(s):  
Case Control ◽  
Case Control Studies

Clinical Trials in Thrombosis: Secondary Prevention of Myocardial Infarction

1976 ◽  
Vol 35 (01) ◽  
pp. 049-056 ◽  
Author(s):  
Christian R Klimt ◽  
P. H Doub ◽  
Nancy H Doub
Keyword(s):  
Myocardial Infarction ◽  
Secondary Prevention ◽  
Case Control ◽  
Therapeutic Effects ◽  
Case Control Studies ◽  
Definitive Answer ◽  
Inhibition Of Platelet Aggregation ◽  
Prospective Trials

SummaryNumerous in vivo and in vitro experiments, investigating the inhibition of platelet aggregation and the prevention of experimentally-induced thrombosis, suggest that anti-platelet drugs, such as aspirin or the combination of aspirin and dipyridamole or sulfinpyrazone, may be effective anti-thrombotic agents in man. Since 1971, seven randomized prospective trials and two case-control studies have been referenced in the literature or are currently being conducted, which evaluate the effects of aspirin, sulfinpyrazone, or dipyridamole in combination with aspirin in the secondary prevention of myocardial infarction. A critical review of these trials indicates a range of evidence from no difference to a favorable trend that antiplatelet drugs may serve as anti-thrombotic agents in man. To date, a definitive answer concerning the therapeutic effects of these drugs in the secondary prevention of coronary heart disease is not available.

Sign in / Sign up

Export Citation Format

Share Document